Antibody-Drug Conjugates for Ovarian Cancer — An Interview with Dr Kathleen N Moore

Featuring an interview with Dr Kathleen N Moore, including the following topics:

• Overview of the mechanism of action and pharmacology of antibody-drug conjugates (ADCs) (0:00)
• Comparing toxicities of conventional chemotherapy and ADCs (6:26)
• Potential of ADCs as maintenance therapy for ovarian cancer (11:35)
• Treatment based on platinum sensitivity and homologous recombination-deficiency status (15:10)
• Case: A woman in her mid 70s presenting with Stage IV ovarian cancer receives raludotatug deruxtecan (18:46)
• Case: A woman in her mid 60s with relapsed/refractory ovarian cancer receives mirvetuximab soravtansine (41:22)
• Case: A woman in her early 70s with relapsed/refractory ovarian cancer receives multiple ADCs in clinical trials (45:57)

CME information and select publications